The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

Moby Strategic Performance Drivers and Market Dynamics. Management attributed Q4 performance to a modest year-end budget ...

Biotech company 10x Genomics (NASDAQ:TXG) reported in Q4 CY2025, but sales were flat year on year at $166 million. The ...

Basepair, a leader in cloud-native bioinformatics analysis, and Sciencewerke Pty Ltd, an Australian specialist in research genomics solutions and scientific supply chain integration, today announced a ...

Shares of 10x Genomics rose after the company narrowed its loss in the fourth quarter, beating Wall Street estimates. Shares were up 11% at $19.41 late Friday morning. The stock has gained 60% over ...

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

Cancer is no longer seen as a single genetic error but as a complex, multi-layered disease shaped by DNA mutations, epigenetic changes and even patterns in medical images. New research at ...

At this time, I would like to welcome everyone to the 10x Genomics, Inc. Fourth Quarter and Full Year 2025 Earnings Call.

Current Genomics is now accepting submissions. This journal publishes high-impact research across genome science, including ...

10x Genomics (NASDAQ: TXG) released its Q4 earnings on Thursday, February 12, 2026 at 04:05 PM. Here's what's important from the earnings announcement. 10x Genomics missed estimated earnings by -30.0% ...

I am the Co-founder and CEO of HaystackAnalytics, a life sciences deep-tech company working in clinical genomics. At Haystack ...

Researchers from IIIT Hyderabad are using cutting-edge technologies for early detection of cancer, and more personalised ...